Related Experiment Video
Updated: May 31, 2026
08:09
Isolation, Culture, and Imaging of Human Fetal Pancreatic Cell Clusters
Published on: May 18, 2014
Enzyme replacement therapy for pancreatic insufficiency: present and future.
Aaron Fieker1, Jessica Philpott, Martine Armand
1Division of Digestive Diseases, University of Oklahoma, OKC, OK, USA;
Clinical and Experimental Gastroenterology
|July 15, 2011
Summary
Pancreatic enzyme replacement therapy effectively reduces steatorrhea and fat malabsorption in pancreatic insufficiency. Research focuses on improving enzyme delivery to the duodenum for enhanced treatment efficacy.
Area of Science:
- Gastroenterology
- Nutritional Science
Background:
- Pancreatic enzyme replacement therapy (PERT) is the primary treatment for malabsorption due to pancreatic insufficiency.
- Current PERT is safe and effective in reducing steatorrhea and fat malabsorption.
Purpose of the Study:
- To address limitations in current PERT, focusing on optimizing enzyme delivery to the duodenum.
- To explore novel enzymes and delivery systems for improved therapeutic outcomes.
Main Methods:
- Review of current PERT efficacy and limitations.
- Discussion of ongoing research into new enzyme formulations and delivery mechanisms.
- Exploration of methods for monitoring PERT effectiveness.
Main Results:
- PERT demonstrates efficacy in managing steatorrhea and fat malabsorption.
- Challenges remain in achieving physiologic enzyme delivery, including gastric inactivation and inadequate duodenal mixing.
- New research aims to enhance enzyme action and monitoring.
Conclusions:
- Despite current efficacy, PERT faces challenges in replicating physiologic enzyme delivery.
- Future research is crucial for developing more efficient enzyme replacement therapies and monitoring tools.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:25Chronic Pancreatitis I: Introduction
Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
01:24Chronic Pancreatitis I: Introduction
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...